As a high degree of correlation between EGFR mutations detected in tumors and those presented in cfDNA has been confirmed by two recent meta-analyses [17, 18], EGFR mutation presented in cfDNA may also be useful predictive markers for guiding NSCLC patients to receive EGFR-TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.